Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer

To the Editor:Worldwide,lung cancer,particularly non-small cell lung cancer(NSCLC),is the leading cause of tumor-related death.Cost-effectiveness analysis show no economic benefits for advanced NSCLC patients over chemotherapy.[1]Furthermore,tests such as programmed cell death ligand 1(PD-L1)and tumor mutational burden(TMB)tests,evaluated via immunohistochemical methods and next-generation sequencing,respectively,are widely used for screening potential beneficiaries of immune checkpoint inhibitors(ICIs).However,these two methods have different predictive values,making their comprehensive evaluation the focus of the current controversy.